オハイオ州立大学脳神経外科のNakano Lab（腫瘍幹細胞研究）では、ポスドクを募集します。当研究室はUCLA脳神経外科において2006年に立ち上げ、2009年9月からOSUに移りました。仕事内容は、脳腫瘍の幹細胞性を維持するメカニズム解析、動物モデルを用いた治療法開発です。トレーニングを受けるフェローには、全米、アジア、欧州にまたがって５０を超える共同研究先とのプロジェクトの一部を自ら主導していただきます。コラボレーション先は最近の論文を参照してください。

＜募集要件＞
ポスドク資格：PhD or MD/PhD
生化学と分子生物学の実験手技を有する方（PCR, cloning, Western blot, IHC, ICC, cell culture, cDNA microarray, RNA/DNA handling 等）。in vivoの実験（transplantation, ventricular injection, in utero injection, gene targeting等）が出来る方。ただ、技術より情熱と協調性を重要視します。米国でいずれ自らのラボを独立する夢を目指す方を探しています。

＜期間＞
可能な範囲で早く　2-3年間。３ヶ月ごとに契約内容を見直し、１年ごとに更新。

＜募集人数＞
2名募集。米国内からの候補者は現在インタビューを継続しております。

＜給与＞
各候補者の経験、NIH指導要綱をもとに決定します。

＜グラント＞
1) R01 NS083767 (P.I.: Ichiro Nakano), 7/1/2013-6/30/2018, $1,288,550.00
2) R01 NS087913 (multi P.I.: Ichiro Nakano and Jeremy Rich), 4/15/2014-2/28/2019, $2,024,796.00
3) R21CA175875 (P.I.: Nakano, I), 1/1/2014-12/31/2015, $376,620.00
4) P01 CA163205-01A1 (overall P.I.: Antonio Chiocca and Ichiro Nakano as PI for Glioma Biorepository Core), 4/1/2013-3/31/2018, $10,463.675.00
5) R01 NS (P.I.: Lathia, J and Ichiro Nakano as co-Investigator), 7/1/2013-6/30/2018

新たに１つのR01と１つのR21が取得でき２０１５年から始まります（前者は５年間、後者は２年間）。

＜提出書類＞
CV(English), 3 reference letters, 1 page proposal

＜問い合わせ先＞
Ichiro Nakano, M.D., Ph.D.
Associate Professor,
Director, Brain Cancer Stem Cell Program,
Departments of Neurological Surgery,
Ohio State University
e-mail: dr.ichiro.nakano@gmail.com

＜参考文献（全６９報から。うち３７報が２０１３年以降）＞
1. Cancerous stem cells can arise from pediatric brain tumors. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI. Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83. PMID: 14645703 * Cited >1360 times as of April 2014

2. Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Miyazaki T, Pan Y, Joshi K, Purohit D, Hu B, Demir H, Mazumder S, Okabe S, Yamori T, Viapiano M, Shin-ya K, Seimiya H, and Nakano I. Clin Cancer Res 2012 Mar 1;18(5):1268-80 PMID: 22230766 * Select for the Cover of the issue.

3. Tumor-specific activation of the c-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S, and Nakano I. Stem Cells 2013 Jan 17. doi: 10.1002/stem.1322. PMID: 23339114

4. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim S, Mao P, Kig C, Nardini D, Sobol RW, Chow L, Kornblum HI, Waclaw R, Beullens M, and Nakano I. Stem Cells 2013 Feb 13. doi: 10.1002/stem.1358. PMID: 23404835

5. Mesenchymal Glioma Stem Cells are Maintained by Activated Glycolytic Metabolism Involving Aldehyde Dehydrogenase 1A3. Mao P, Kim SH, Li J, Joshi K, Li PP, Santana-Santos L, Luthra S, Chandran UR, Benos PV, Smith L, Wang MD, Hu B, Cheng SY, Sobol RW, Nakano I. Proc Natl Acad Sci U S A. 2013 May 21;110(21):8644-9. PMID: 23650391

6. Crosstalk between glioma initiating cells and endothelial cells drives tumor progression. Jeon HM, Kim SH, Park JB, Kim SH, Nakano I, Kim H. Cancer Research 2014 Aug 15;74(16):4482-92. doi: 10.1158/0008-5472.CAN-13-1597.

7. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin/Ran protein complex. Guvenc H*, Pavlyukov MS*, Kurt H, Joshi K Banasavadi-Siddegowda YK, Mao P, Hong C, Yamada R, Kwon CH, Kitange G, Park IH, Sarkaria JN, Li C, Shakhparonov MI, Nakano I. Clin Cancer Res 2013 Feb 1;19(3):631-42. PMID: 23251006

8. Phosphorylation of a Polycomb component EZH2 by AKT activates STAT3 and promotes self-renewal and tumorigenicity of glioblastoma stem-like cells. Kim E, Kim M, ShinY, Joo KM, Woo DH, Chang N, Oh Y, Rheey J, Nakano I, Rich JN, Nam DH, Lee J. Cancer Cell 2013 Jun 10;23(6):839-52 PMID: 23684459

9. Mesenchymal Differentiation Mediated by NFB Promotes Radiation Resistance in Glioblastoma. Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, denDunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, and Aldape K. Cancer Cell 2013 Sep 9;24(3):331-46. doi: 10.1016/j.ccr.2013.08.001.

10.Brain Tumor Initiating Cells Adapt to Restricted Nutrition through Preferential Glucose Uptake. Flavahan W, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, Li M, Lathia JD, Rich JN, Hjelmeland AB. Nature Neuroscience 2013 Oct;16(10):1373-82. doi: 10.1038/nn.3510.

11. Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Bronisz A, Wang Y, Nowicki MO, Peruzzi P, Ansari K, Ogawa D, Balaj L, Derienzo G, Mineo M, Nakano I, Ostrowski MC, Hochberg F, Weissleder R, Lawler SE, Chiocca EA, Godlewski J. Cancer Res. 2013 Dec 5. [Epub ahead of print]

12. Maintenance of the glioblastoma cellular hierarchy is regulated by junctional adhesion molecule-A. Lathia JD, Li M, Sathyan P, Hale J, Zinn P, Gallagher J, Wu Q, Sinyuk M, Nakano I, McLendon RE, Sloan AE, Carson C, Naik U, Hjelmeland AB, Majumder S, Rich JN, Cell Reports 2014 Jan 16;6(1):117-29. doi: 10.1016/j.celrep.2013.11.043. PMID: 24373972

13. Multi-Kinase Inhibitor C1 Triggers Mitotic Catastrophe of Glioma Stem Cells Mainly through MELK Kinase Inhibition. Minata M, Gu C, Joshi K, Nakano-Okuno M, Hong C, Nguyen CH, Kornblum HI, Molla A, Nakano I.
PLoS One. 2014 Apr 16;9(4):e92546. doi: 10.1371/journal.pone.0092546. PMID: 24739874

14. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner. Kim SH, Joshi K, Ezhilarasan R, Myers TR, Siu J, Gu C, Nakano-Okuno M, Taylor D, Minata M, Sulman EP, Lee J, Bhat KP, Salcini AE, and Nakano I. Stem Cell Reports 2015 [in press]